PD-L1 IHC 28–8 pharmDx (14) was developed to detect PD-L1 expression and facilitate the safe and effective use of the PD-1 inhibitor nivolumab in patients with NSCLC (24). This evidence concerns the gene CD274 and non-small cell lung carcinoma.